BR9611210A - Composições e processos para tratamento de condições ósseas deficitárias - Google Patents
Composições e processos para tratamento de condições ósseas deficitáriasInfo
- Publication number
- BR9611210A BR9611210A BR9611210-7A BR9611210A BR9611210A BR 9611210 A BR9611210 A BR 9611210A BR 9611210 A BR9611210 A BR 9611210A BR 9611210 A BR9611210 A BR 9611210A
- Authority
- BR
- Brazil
- Prior art keywords
- bone
- compositions
- processes
- ability
- development
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Abstract
Patente de Invenção: <B>"COMPOSIçõES E PROCESSOS PARA TRATAMENTO DE CONDIçõES óSSEAS DEFICITáRIAS"<D>. Compostos contendo dois sistemas aromáticos covalentemente ligados através de um ligante contendo um ou mais átomos, ou "ligante" definido como incluindo uma ligação covalente por si, de modo a espaçar os sistemas aromáticos a uma distância de 1,5-15<sym> são eficazes nas condições de tratamento associados aos déficits ósseos. Os compostos podem ser administrados aos indivíduos vertebrados sozinhos ou em combinação com agentes adicionais que promovem o desenvolvimento ósseo ou que inibam a ressorção ósseas. Eles podem ser classificados por atividade antes da administração por avaliar sua capacidade de efetuar a transição de um gene repórter acoplado a um promotor associado a uma proteína morfogenética ósse e/ou sua capacidade de estimular o desenvolvimento calvarial nos sistemas animais modelos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US583095P | 1995-10-23 | 1995-10-23 | |
PCT/US1996/017019 WO1997015308A1 (en) | 1995-10-23 | 1996-10-23 | Compositions and methods for treating bone deficit conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9611210A true BR9611210A (pt) | 1999-12-28 |
Family
ID=21717974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9611210-7A BR9611210A (pt) | 1995-10-23 | 1996-10-23 | Composições e processos para tratamento de condições ósseas deficitárias |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0866710A4 (pt) |
JP (1) | JP2000513324A (pt) |
KR (1) | KR19990067010A (pt) |
CN (1) | CN1201393A (pt) |
AU (1) | AU706262B2 (pt) |
BR (1) | BR9611210A (pt) |
CA (1) | CA2235481A1 (pt) |
CZ (1) | CZ115398A3 (pt) |
EA (1) | EA199800393A1 (pt) |
HU (1) | HUP9802319A3 (pt) |
NO (1) | NO981810L (pt) |
PL (1) | PL327617A1 (pt) |
WO (1) | WO1997015308A1 (pt) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL330814A1 (en) | 1996-06-20 | 1999-06-07 | Regents Board Of | Compounds for and methods of delivering pharmaceutical preparations and their application |
WO1998017267A1 (en) * | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
US6080779A (en) * | 1996-12-13 | 2000-06-27 | Osteoscreen, Inc. | Compositions and methods for stimulating bone growth |
US6376476B1 (en) | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
AU8748798A (en) * | 1997-08-22 | 1999-03-16 | Kyowa Hakko Kogyo Co. Ltd. | 4-aminoquinazoline derivatives |
US6649631B1 (en) | 1997-10-23 | 2003-11-18 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating bone deficit conditions |
DE19812204A1 (de) * | 1998-03-19 | 1999-11-04 | Plantamed Arzneimittel Gmbh | Verwendung von Extrakten aus Cimicifuga racemosa und Belamcanda sinensis als estrogenartiges organselektives Arzneimittel ohne uterotrope Wirkung |
JP2000004882A (ja) * | 1998-06-18 | 2000-01-11 | Hoechst Marion Roussel Kk | ヒトmp52遺伝子プロモーターおよびこれを用いた有用物質の探索法 |
US6902721B1 (en) | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6838436B1 (en) | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6462036B1 (en) | 1998-11-06 | 2002-10-08 | Basf Aktiengesellschaft | Tricyclic pyrazole derivatives |
JP2003517447A (ja) * | 1998-11-06 | 2003-05-27 | ビーエーエスエフ アクチェンゲゼルシャフト | 三環式ピラゾール誘導体 |
AU5250400A (en) * | 1999-06-18 | 2001-01-09 | Mitsubishi Pharma Corporation | Osteogenesis promoters |
WO2001017562A1 (en) * | 1999-09-02 | 2001-03-15 | Yamanouchi Pharmaceutical Co., Ltd. | Osteogenesis promoting agents |
KR100641802B1 (ko) | 1999-12-28 | 2006-11-02 | 에자이 가부시키가이샤 | 술폰아미드 함유 복소환 화합물 |
FR2806408B1 (fr) * | 2000-03-17 | 2002-10-11 | Oreal | Composition cosmetique comprenant un derive de furane- naphtoquinone, leur utilisation comme agent colorant et derives |
EP1361224B1 (de) | 2000-06-05 | 2005-12-28 | Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung | Heterocyclische Hydrazone als anti-Krebs-Wirkstoffe |
US6660737B2 (en) | 2001-05-04 | 2003-12-09 | The Procter & Gamble Company | Medicinal uses of hydrazones |
US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
JPWO2003082808A1 (ja) * | 2002-04-03 | 2005-08-04 | 住友製薬株式会社 | ベンズアミド誘導体 |
US20050260126A1 (en) * | 2002-08-30 | 2005-11-24 | Yukitsuka Kudo | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein |
WO2004054978A1 (ja) * | 2002-12-16 | 2004-07-01 | Bf Research Institute, Inc. | タウ蛋白蓄積性疾患の診断プローブとしてのキノリン誘導体 |
AU2004209456A1 (en) | 2003-02-03 | 2004-08-19 | Janssen Pharmaceutica N.V. | Quinoline-derived amide modulators of vanilloid VR1 receptor |
ES2389907T3 (es) | 2004-04-30 | 2012-11-02 | Takeda Pharmaceutical Company Limited | Compuesto de amida heterocíclica y uso del mismo como un inhibidor de MMP-13 |
AR052674A1 (es) | 2005-02-17 | 2007-03-28 | Wyeth Corp | Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados |
PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
WO2009076792A1 (en) | 2007-12-19 | 2009-06-25 | Givaudan Sa | Cooling compounds |
EP2346837B8 (en) | 2008-06-26 | 2015-04-15 | Resverlogix Corporation | Methods of preparing quinazolinone derivatives |
EP2382194B1 (en) | 2009-01-08 | 2014-03-12 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
US8822462B2 (en) * | 2009-01-28 | 2014-09-02 | Emory University | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions |
NZ708314A (en) | 2009-03-18 | 2017-08-25 | Resverlogix Corp | Quinazolinones for use as anticancer agents |
BRPI1014956B8 (pt) | 2009-04-22 | 2021-05-25 | Resverlogix Corp | agentes anti-inflamatórios |
PL2773354T3 (pl) | 2011-11-01 | 2019-12-31 | Resverlogix Corp. | Doustna formulacja o natychmiastowym uwalnianiu dla podstawowych chinazolinów |
US9388138B2 (en) | 2012-07-18 | 2016-07-12 | University College Dublin National University Of Ireland, Dublin | Anti-angiogenic compounds |
CN102942515A (zh) * | 2012-10-22 | 2013-02-27 | 暨南大学 | 一种乙烯桥连吲哚化合物及其合成方法和用途 |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
JP2016507496A (ja) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. | ブロモドメイン阻害剤としての新規複素環式化合物 |
JO3789B1 (ar) | 2015-03-13 | 2021-01-31 | Resverlogix Corp | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة |
CN107019687B (zh) * | 2017-05-08 | 2020-10-27 | 上海市伤骨科研究所 | N-(4-氯苯基)-3-羟基-2-萘甲酰胺类化合物的用途 |
CN111116552B (zh) * | 2020-01-17 | 2022-10-11 | 河北科技大学 | 一种喹唑啉酮类化合物及其制备方法 |
CN114469863B (zh) * | 2021-11-26 | 2023-09-26 | 南方医科大学南方医院 | 甾醇脂质体作为牙髓和牙本质药物传递***的应用 |
CN116650495B (zh) * | 2021-12-10 | 2024-04-19 | 中南大学湘雅医院 | 芳香族化合物作为神经丛素蛋白-b2的激活剂以及在制备治疗骨质疏松症药物中的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4889851A (en) * | 1986-11-21 | 1989-12-26 | Fujisawa Pharmaceutical Co, Ltd. | Benzothiadiazine compounds, and pharmaceutical composition comprising the same |
JP2724396B2 (ja) * | 1987-12-18 | 1998-03-09 | 武田薬品工業株式会社 | 骨粗鬆症予防治療剤 |
EP0536119A4 (en) * | 1989-02-10 | 1993-08-04 | Washington Research Foundation | Immunoregulatory agents |
JPH06192272A (ja) * | 1992-12-24 | 1994-07-12 | Japan Tobacco Inc | 新規なトリアゾロベンゾチアジアジン及びトリアゾロベンゾチアジアゼピン誘導体 |
US5280040A (en) * | 1993-03-11 | 1994-01-18 | Zymogenetics, Inc. | Methods for reducing bone loss using centchroman derivatives |
EP0716086A1 (en) * | 1994-12-09 | 1996-06-12 | Boehringer Mannheim Gmbh | Malonic acid based matrix metalloproteinase inhibitors |
WO1998017267A1 (en) * | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
EP0944312B9 (en) * | 1996-12-13 | 2006-07-05 | ZymoGenetics, Inc. | Compositions and methods for stimulating bone growth |
-
1996
- 1996-10-23 PL PL96327617A patent/PL327617A1/xx unknown
- 1996-10-23 EP EP96936906A patent/EP0866710A4/en not_active Withdrawn
- 1996-10-23 CZ CZ981153A patent/CZ115398A3/cs unknown
- 1996-10-23 AU AU74710/96A patent/AU706262B2/en not_active Ceased
- 1996-10-23 EA EA199800393A patent/EA199800393A1/ru unknown
- 1996-10-23 CN CN96197827A patent/CN1201393A/zh active Pending
- 1996-10-23 JP JP09516761A patent/JP2000513324A/ja active Pending
- 1996-10-23 WO PCT/US1996/017019 patent/WO1997015308A1/en not_active Application Discontinuation
- 1996-10-23 CA CA002235481A patent/CA2235481A1/en not_active Abandoned
- 1996-10-23 BR BR9611210-7A patent/BR9611210A/pt not_active Application Discontinuation
- 1996-10-23 HU HU9802319A patent/HUP9802319A3/hu unknown
- 1996-10-23 KR KR1019980702947A patent/KR19990067010A/ko not_active Application Discontinuation
-
1998
- 1998-04-22 NO NO981810A patent/NO981810L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0866710A4 (en) | 2001-07-11 |
HUP9802319A3 (en) | 1999-12-28 |
EA199800393A1 (ru) | 1998-12-24 |
NO981810L (no) | 1998-06-22 |
AU706262B2 (en) | 1999-06-10 |
JP2000513324A (ja) | 2000-10-10 |
WO1997015308A1 (en) | 1997-05-01 |
NO981810D0 (no) | 1998-04-22 |
AU7471096A (en) | 1997-05-15 |
EP0866710A1 (en) | 1998-09-30 |
CA2235481A1 (en) | 1997-05-01 |
CZ115398A3 (cs) | 1998-12-16 |
CN1201393A (zh) | 1998-12-09 |
KR19990067010A (ko) | 1999-08-16 |
HUP9802319A2 (hu) | 1999-02-01 |
PL327617A1 (en) | 1998-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9611210A (pt) | Composições e processos para tratamento de condições ósseas deficitárias | |
BR9711805A (pt) | Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos | |
BR9917082A (pt) | Compostos inibidores da produção de proteìnas a"beta", método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase | |
BR0206689A (pt) | Combinação de probióticos, e, uso desta | |
BR9815159A (pt) | Preparação de conjugados de polietileno glicol-grf especìfica ao sìtio | |
BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
BR0214757A (pt) | Formulações farmacêuticas de derivados de platina | |
HRP20010877B1 (en) | Composition for prevention and treatment of amyloidogenic disease | |
BR0013010A (pt) | Formulação de cloreto de sódio de moxifloxacina | |
FI962591A0 (fi) | Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä | |
BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
BR9811093A (pt) | Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo) | |
ES2109260T3 (es) | Eritrocitos transformados, procedimiento para prepararlos y su utilizacion en composiciones farmaceuticas. | |
ES2133329T3 (es) | Variantes de il-3 humana. | |
TR200101649T2 (tr) | Piperazin türevleri. | |
BR9810703A (pt) | Composição farmacêutica, e, processos para a preparação da mesma, e para tratar um distúrbio de agregação de plaqueta | |
TR200100637T2 (tr) | Yeni doğal ürün türevleri | |
BR0006088A (pt) | Derivados de proteìna c | |
BR9908716A (pt) | Tratamento de disfunção sexual em certos grupos de pacientes | |
BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
BR9915071A (pt) | Utilização de uma proteìna ompa de enterobactéria ou de um de seus fragmentos | |
BG103905A (en) | New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine | |
DE69621786D1 (de) | Aminotetralinderivat zur behandlung von herzkreislauferkrankung | |
RU95110774A (ru) | Олигонуклеотиды, терапевтические композиции, применение композиций | |
BR0004813A (pt) | Constructos vesiculares marcados para citoproteção e tratamento de infecções por h. pylori |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA10 | Dismissal: dismissal - article 33 of industrial property law |